Psychedelic Therapy and Retreat Centers: A Global Overview

Related: looking for a one-on-one integration therapist instead of a retreat center? See the Psychedelic Therapist Directory. Considering training to become a facilitator yourself? See the Psychedelic Education Courses Directory.

Quick Comparison: Where Can You Legally Access Psilocybin Services?

For full legal detail and official sources per jurisdiction, see United States, Netherlands, and Jamaica country pages. Colorado does not yet have a dedicated legal/countries/ page (US federal + state nuance is covered on the United States page); a Colorado-specific Regional Guide exists with travel/cultural context.

Oregon Psilocybin Services: The First Licensed State Regulatory Framework

Oregon Measure 109, passed alongside Measure 110 in November 2020, created the first state-licensed psilocybin service framework in the United States. Unlike a medical model (which would require a clinical diagnosis), Measure 109 established psilocybin as a "service" that any adult over 21 can access at a licensed service center without a prescription or diagnosis. The Oregon Health Authority spent two years developing rules, which were finalized in 2022, and the first service centers began opening to clients in 2023 after completing licensing requirements.

The regulatory structure has several key features. Facilitators must complete a minimum 120-hour training program at an approved psilocybin facilitator training program — training that covers set and setting, safety protocols, integration support, and crisis intervention. Training programs themselves must be licensed by the state. Service centers must be licensed premises where psilocybin is grown, manufactured, and administered under state-controlled conditions. Psilocybin cannot be taken off-premises. Sessions typically last 4–8 hours, reflecting the natural duration of a psilocybin experience, and include a preparation session before and an integration session after the psilocybin experience itself.

Among the first licensed service centers to open were Synthesis (operating in Portland under its Oregon license), InnerTrek (which also operates one of the state's facilitator training programs), and Mynd Medicine. Costs at licensed centers have ranged from approximately $500 to $3,000 per session, reflecting the overhead of licensed premises, trained facilitators, and the psilocybin product itself. Notably, because Measure 109 explicitly does not frame psilocybin as "therapy" (which would require medical licensing), facilitators operate in a paraprofessional capacity — they provide support and presence, not clinical treatment. Therapists and psychologists who wish to integrate psilocybin sessions into their clinical practice must do so through separate pathways.

The Oregon model is being closely watched nationally and internationally as a potential template. Colorado's Proposition 122, which created a similar "natural medicine" healing center framework for multiple substances, modeled many elements of its regulatory structure on the Oregon approach.

Colorado: The Natural Medicine Health Act and a Broader Substance Scope

Colorado voters passed Proposition 122 (the Natural Medicine Health Act) in November 2022, creating the second US state-level framework for regulated psilocybin access — and the first to cover multiple natural psychedelics in one law. Unlike Oregon's Measure 109, which addresses psilocybin specifically, Colorado's law also decriminalizes personal use of psilocin, DMT, ibogaine, and non-peyote-derived mescaline for adults 21 and older, alongside creating a licensed "healing center" model for supervised psilocybin (and eventually other substances) sessions regulated by the Colorado Department of Regulatory Agencies (DORA).

Two distinct legal tracks exist side by side in Colorado. First, personal use: adults 21+ may possess, use, grow at home, and share (not sell) psilocybin mushrooms without a license — a more permissive personal-use allowance than Oregon offers. Second, the licensed healing center track: supervised sessions with a trained facilitator at a DORA-licensed healing center, which began operating from 2024, following a regulatory buildout period similar to Oregon's. As with Oregon, no medical diagnosis or prescription is required to access a healing center session.

Because Colorado's licensed healing center system is newer than Oregon's (with the first licenses issued in 2024, roughly a year after Oregon's first service centers opened in 2023), pricing and center availability are less established and more prone to change. For current details, see the dedicated Colorado Regional Guide and the United States legal status page, both of which are reviewed and updated separately from this overview.

The Netherlands: Psilocybin Truffles and the Legal Loophole

The Netherlands operates under a drug policy peculiarity that has made it a hub for psilocybin retreat tourism since the early 2000s. Under the Dutch Opium Act of 1976, psilocybin-containing mushrooms (fruiting bodies) were explicitly listed as a controlled substance, but the underground structures from which mushrooms grow — known as sclerotia, or "truffles" — were not included in the original scheduling. When Dutch authorities moved to ban magic mushrooms in 2008 following a series of tourist incidents in Amsterdam, they banned the fruiting bodies but left psilocybin truffles unaddressed, creating a legal distinction that persists today.

Dutch retreat centers operating with psilocybin truffles have proliferated in the years since, clustered primarily in Amsterdam and its surroundings. These are not medical facilities — Dutch law does not license psilocybin therapy — but retreat operators have developed sophisticated frameworks that borrow elements from therapeutic practice: medical intake screening, preparation sessions, ceremonial or psychologically supportive facilitation during the experience, and integration support. Programs typically run three to five days, with the psilocybin experience (often two sessions on consecutive days) as the centerpiece. Synthesis, the retreat center that later moved to the Oregon licensing model, was among the most prominent of the Dutch operators before relocating its primary operations.

Dutch operators face significant legal constraints around marketing. Advertising psilocybin retreats as "therapy" for mental health conditions would invite regulatory scrutiny from Dutch health authorities, so most centers frame their services in terms of personal development, wellness, and self-exploration. This creates ambiguity for individuals seeking help with specific conditions like depression or PTSD — the retreat context may be supportive, but it is not equivalent to a clinical trial or licensed therapeutic service.

Jamaica: Full Legal Status and Medical Tourism

Jamaica is the only country in the Western Hemisphere where psilocybin mushrooms have never been scheduled as controlled substances. The Dangerous Drugs Act of Jamaica does not list psilocybin or psilocin, meaning their cultivation, possession, use, and sale are entirely legal. This has made Jamaica the most legally permissive jurisdiction for psilocybin in the world, and has supported the development of a growing medical tourism industry centered on psilocybin retreats.

MycoMeditations, operating from Treasure Beach on Jamaica's south coast, was among the earliest operators to develop a medically-adjacent psilocybin retreat model. Founded by Eric Osborne, it offers structured week-long programs that include psychological preparation, three high-dose psilocybin group sessions (typically 3.5–5 grams of dried mushrooms), and integration support. Clients are screened for contraindicated medical and psychological conditions before enrollment. Atman Retreat and BEHOLD Retreats are among the other established operators. Program costs typically range from $2,000 to $6,000 or more depending on duration, accommodation quality, and level of individualized support — placing them within reach of medically motivated travelers from North America and Europe, but not accessible to most people globally.

Jamaica's legal status makes it particularly attractive to American citizens who cannot legally access psilocybin at home but are willing to travel for a facilitated experience in a safe, supervised setting. Several Jamaica-based operators have begun partnering with U.S.-based mental health professionals, creating referral pipelines in which therapists connect clients to Jamaican retreats and then provide integration therapy upon the client's return. This cross-border model exists in a regulatory gray area regarding professional licensure but has become increasingly common in the broader psychedelic ecosystem.

Academic and Clinical Research Centers

While not retreat centers, the major clinical research institutions studying psilocybin are central to the global therapeutic landscape. The Johns Hopkins Center for Psychedelic and Consciousness Research, established in 2019, is the largest dedicated psychedelic research center in the United States. Founded with $17 million in private funding, it was home to Roland Griffiths (who died in 2023 after a cancer diagnosis that itself became the subject of research into psilocybin for existential distress) and Matthew Johnson, who has led landmark studies on psilocybin for smoking cessation, major depressive disorder, and Alzheimer's-related anxiety. Johns Hopkins research consistently produces the most-cited psilocybin clinical studies and has shaped the protocol standards adopted by subsequent researchers worldwide.

NYU Langone's Psychedelic Medicine Program, led by Michael Bogenschutz and others, has focused on psilocybin for alcohol use disorder and major depression. Author Michael Pollan's influential 2018 book "How to Change Your Mind" drew heavily on his reporting from NYU's program, bringing psilocybin therapy to mainstream public awareness. The program has since expanded its research portfolio and its therapist training offerings. Imperial College London's Centre for Psychedelic Research, founded by Robin Carhart-Harris (who has since moved to UC San Francisco) produced foundational neuroscience on psilocybin's effects on the default mode network and brain connectivity, providing the mechanistic framework that informs most current hypotheses about how psilocybin produces therapeutic effects.

Usona Institute, a nonprofit medical research organization based in Wisconsin, holds a separate Investigational New Drug (IND) application for psilocybin distinct from the commercial programs run by Compass Pathways. Usona's mission is to develop psilocybin as a non-proprietary treatment available to the broadest possible population, in contrast to pharmaceutical companies that may seek patents on formulations or delivery methods. Usona's Phase 2 trial data for major depressive disorder demonstrated a single psilocybin session producing rapid and durable antidepressant effects, adding to the clinical evidence base.

Frequently Asked Questions

How is Colorado's psilocybin framework different from Oregon's?

Colorado's Proposition 122 (2022) covers more substances than Oregon's Measure 109 (psilocybin only) — it also decriminalizes personal use of psilocin, DMT, ibogaine, and non-peyote mescaline. Colorado also allows personal possession, home growing, and non-commercial sharing for adults 21+ without any license, which Oregon does not. Both states share a licensed "service center" / "healing center" model for supervised sessions without requiring a medical diagnosis. Colorado's licensed healing centers began operating in 2024, about a year after Oregon's first service centers opened in 2023, so the Colorado market is comparatively newer and less established.

Can I access psilocybin services in Oregon without a medical diagnosis?

Yes. Oregon's Measure 109 framework deliberately does not require a medical diagnosis or prescription to access psilocybin services. Any adult aged 21 or older can visit a licensed service center, complete a preparation session with a licensed facilitator, and undergo a psilocybin session. The system is framed as a "service" rather than medical treatment. However, service centers conduct health screenings and may decline to facilitate sessions for individuals with certain medical or psychiatric contraindications.

Are psilocybin mushrooms legal in the Netherlands?

Psilocybin-containing mushroom fruiting bodies (what most people call "magic mushrooms") are illegal in the Netherlands under the 1976 Opium Act. However, psilocybin truffles (sclerotia) — the underground fungal structures that were not included in the 2008 mushroom ban — remain unscheduled and are sold legally in smart shops and used in retreat programs. The distinction is legally significant but pharmacologically irrelevant: truffles contain the same psilocybin and psilocin as mushrooms.

Why is Jamaica popular for psilocybin retreats?

Jamaica has never scheduled psilocybin or psilocin under its Dangerous Drugs Act, making it one of the only jurisdictions in the world where the cultivation, possession, sale, and use of psilocybin mushrooms is entirely legal. This allows retreat operators to work openly, without the legal ambiguity that characterizes the Dutch truffle model or the restricted licensed framework of Oregon. Jamaica's favorable climate, natural beauty, and proximity to North America have made it an attractive destination for medical tourism focused on psilocybin-assisted healing.

How long is an Oregon psilocybin session?

Oregon psilocybin sessions typically last 4–8 hours, reflecting the natural duration of a psilocybin experience at therapeutic doses (usually 25mg of synthetic psilocybin or the equivalent in dried mushroom material). Clients remain at the licensed service center throughout the session, supported by a licensed facilitator. The session is preceded by a preparation meeting and followed by an integration session. Total client time across the three-part program (preparation, session, integration) commonly runs 6–12 hours.

What is the difference between an Oregon licensed facilitator and a psychedelic therapist?

An Oregon licensed psilocybin facilitator completes a 120-hour state-approved training and is licensed to provide psilocybin services in licensed facilities. Facilitators are not therapists — they cannot diagnose, treat, or bill insurance, and they are trained to provide supportive presence rather than clinical intervention. A psychedelic therapist, by contrast, holds a clinical license (psychologist, LCSW, psychiatrist) and integrates psychedelic experiences into a broader therapeutic relationship. Some Oregon facilitators also hold clinical licenses, but the roles are legally distinct.

Who was Roland Griffiths?

Roland Griffiths was a pharmacologist and Professor of Psychiatry and Neuroscience at Johns Hopkins University who is widely regarded as the most influential figure in the modern clinical renaissance of psilocybin research. His landmark 2006 paper in Psychopharmacology demonstrating that psilocybin can reliably occasion "mystical-type experiences having substantial and sustained personal meaning" is cited as the study that reopened the door to serious scientific investigation. Griffiths went on to lead studies on psilocybin for smoking cessation, depression, and existential distress in cancer patients. He died in October 2023 following a diagnosis of colon cancer, with which he had engaged in his own psilocybin research.

What is Usona Institute and why is it significant?

Usona Institute is a nonprofit medical research organization based in Wisconsin that holds an Investigational New Drug (IND) application for psilocybin for major depressive disorder. Unlike commercial pharmaceutical companies, Usona's mission explicitly rejects proprietary control over psilocybin treatments — it aims to develop psilocybin therapy as a non-patented, widely accessible treatment. This contrasts with Compass Pathways, which has sought intellectual property protection for aspects of its psilocybin therapy program. Usona's Phase 2 data showed a single psilocybin session producing statistically significant antidepressant effects.

Can U.S. therapists legally refer clients to Jamaican retreat centers?

The legal landscape for this practice is unsettled. A licensed U.S. therapist who refers a client to a Jamaican retreat center is not violating U.S. drug laws (since no controlled substance transaction occurs in the U.S.), but professional licensing boards in some states may interpret such referrals as outside the scope of professional practice or as facilitating the use of substances that are federally illegal in the U.S. Several professional psychedelic therapy training programs include guidance on the ethics and legal considerations of cross-border referrals, and the practice is becoming more common even as its regulatory status remains ambiguous.

What is the cost of a psilocybin session in Oregon?

Costs at Oregon licensed service centers have ranged widely, from approximately $500 for lower-cost community-oriented programs to $2,000–$3,000 or more for higher-end facilitators with mental health backgrounds. The cost reflects licensed premises overhead, facilitator training and compensation, insurance, and the psilocybin product itself. Oregon psilocybin services are not covered by health insurance. Some service centers offer sliding-scale fees or scholarship programs to improve access, recognizing that current pricing limits the demographics who can benefit from the new regulatory system.

What is the role of Imperial College London in psilocybin research?

Imperial College London's Centre for Psychedelic Research, founded by Robin Carhart-Harris, produced foundational neuroscience work on psilocybin's effects on brain connectivity and the default mode network (DMN) — the brain network associated with self-referential thought and rumination that is often hyperactive in depression and anxiety. Imperial's research provided the neural mechanistic framework that supports the therapeutic hypothesis: psilocybin's temporary disruption of DMN activity may allow for cognitive flexibility and relief from rigid negative thought patterns. Carhart-Harris moved from Imperial to UC San Francisco in 2021, where he continues this line of research.